No Data
No Data
Mochida Pharmaceutical: Interim report
Mochida Pharmaceutical: Confirmatory letter.
Mochida Pharmaceutical: Securities Report - 86th Fiscal Year (April 01, 2023 - March 31, 2024)
Investment Strategy for June 24th [Today]
[FISCO Selected Stock] [Material Stock] Vision <9416> handles web marketing support and Wi-Fi router rental. The financial estimates for the year ending December 2024 have been upwardly revised. Operating profit is expected to be 5.707 billion yen (+33.3% YoY). This is about 8% higher than the previous estimate. While there is a delay in the recovery of Japanese overseas travel demand, the upward revision was due to the improvement in gross profit margin in the first half and other factors. The annual dividend estimate is 27 yen. Previous estimate.
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○ List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime <1720> Tokyu Construction 801 855 <1801> Taiseiken 5512 6015 <1802> Obayashi Corporation 1677 1780 <1803> Shimizu 949 1050 <1808> Haseko 1845 19
Pursue high-growth companies! Fiscal Year Ending 25/3 [Increase in Sales and Profit] List <Special Feature on Growth Stocks> 5/13 Edition
As financial results announcements for the fiscal year ending March 24 are in full swing, market attention is focused on the earnings forecast for the fiscal year ending 25/3, which will be announced at the same time. This special issue shines a spotlight on companies that anticipate an increase in sales and profit for the fiscal year ending 25/3 from the financial results announced today. In the table below, 54 companies with a total market value of 10 billion yen or more were selected for stocks with a total market value of 10 billion yen or more, and that both surpassed previous fiscal year results for the fiscal year ending 25/3, and ordinary profit showed an expected increase of 10% or more, and arranged them in order of the highest profit increase rate.
No Data